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Abstract
Background: There is considerable interest in the hypothesis that low frequency, intermediate penetrance variants
contribute to the proportion of Type 2 Diabetes (T2D) susceptibility not attributable to the common variants uncovered
through genome-wide association approaches. Genes previously implicated in monogenic and multifactorial forms of
diabetes are obvious candidates in this respect. In this study, we focussed on exons 8–10 of the HNF1A gene since rare,
penetrant mutations in these exons (which are only transcribed in selected HNF1A isoforms) are associated with a later age
of diagnosis of Maturity onset diabetes of the young (MODY) than mutations in exons 1–7. The age of diagnosis in the
subgroup of HNF1A-MODY individuals with exon 8–10 mutations overlaps with that of early multifactorial T2D, and we set
out to test the hypothesis that these exons might also harbour low-frequency coding variants of intermediate penetrance
that contribute to risk of multifactorial T2D.
Methodology and Principal Findings: We performed targeted capillary resequencing of HNF1A exons 8–10 in 591
European T2D subjects enriched for genetic aetiology on the basis of an early age of diagnosis (#45 years) and/or family
history of T2D ($1 affected sibling). PCR products were sequenced and compared to the published HNF1A sequence. We
identified several variants (rs735396 [IVS9224T.C], rs1169304 [IVS8+29T.C], c.1768+44C.T [IVS9+44C.T] and rs61953349
[c.1545G.A, p.T515T] but no novel non-synonymous coding variants were detected.
Conclusions and Significance: We conclude that low frequency, nonsynonymous coding variants in the terminal exons of
HNF1A are unlikely to contribute to T2D-susceptibility in European samples. Nevertheless, the rationale for seeking low-
frequency causal variants in genes known to contain rare, penetrant mutations remains strong and should motivate efforts
to screen other genes in a similar fashion.
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Introduction
HNF1A encodes the transcription factor hepatocyte nuclear
factor 1 alpha and is the gene most commonly implicated in the
pathogenesis of symptomatic Maturity-onset diabetes of the young
(MODY) [1]. HNF1A encodes 3 different isoforms, termed A
(encoded by exons 1–10), B (encoded by exons 1–7) and C
(encoded by exons 1–6) which arise by alternative splicing and
polyadenylation [2]. Two recent reports have demonstrated that
mutations in exons 8–10 (which are present only in isoform A) are
associated with a later onset of MODY than is the case for
mutations in exons 1–7 (18 vs. 25 years, p=0.0001 and 19 vs. 24
years, p=0.03) [3,4]. This difference in presentation is likely to
reflect the different temporal and spatial expression profiles of the
isoforms (isoform A predominates in the foetal pancreas, adult
liver and kidney whilst isoforms B and C predominate in the adult
pancreas). Thus, in contrast with mutations which affect the
function of all isoforms, mutations in exons 8–10 may display a
lower penetrance and later age of onset leading to more clinical
overlap with common forms of Type 2 diabetes mellitus (T2D).
Despite the great success of the genome wide association (GWA)
approach in identifying common genetic variants which predis-
pose to T2D, the familial aggregation seen in this condition is far
from fully explained [5]. The sibling relative risk (ls) for T2D
attributable to all currently-known susceptibility variants com-
bined is only ,1.07, well below the equivalent estimate from
epidemiological studies of ,3.0 [5]. Ongoing efforts to account for
this ‘‘heritability gap’’ are increasingly aimed at identification of
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intermediate penetrance (allelic odds ratios, 2–5) variants. Variants
with such characteristics are likely to have remained hidden from
view so far, since their frequency is below that targeted by GWA
approaches, and the penetrance is insufficient for detection by
traditional linkage analyses[6]. Variants with these characteristics
have recently been recognised to contribute to susceptibility of
other complex traits such as Crohn’s disease [7].
Genes already known to play a role in the pathogenesis of
monogenic or multifactorial diabetes are logical candidates in
which to initiate the search for low frequency causal variants in
T2D. In the case of HNF1A for example, there is evidence that a
private common variant (G319S, located in exon 4) is a major
contributor to T2D pathogenesis in the Oji-Cree population (in
whom the MAF is 8.7%) [8,9]. Further evidence that HNF1A
variants across the allele frequency spectrum play a role in T2D-
susceptibility derives from evidence that common variants in this
gene are associated with multifactorial T2D [10–12].
In the light of this evidence, we reasoned that the terminal
isoform-specific exons of HNF1A were particularly auspicious
candidates in terms of harbouring low frequency, medium-
penetrance variants involved in multifactorial diabetes. We set
out to test this hypothesis by performing deep resequencing of
these exons in a large sample of cases likely to be enriched for such
variants, namely those with a strong family history of T2D and/or
an early age at diagnosis.
Materials and Methods
Ethics Statement. All subjects gave written informed consent
and all protocols were approved by the local ethics committees.
The Warren 2 Sibpair collection was approved by multiple local
ethics committees in the UK including St Mary’s Local Ethics
Committee (EC3231). The Young Diabetes in Oxford Cohort was
approved by the Oxfordshire Research Ethics Committee A (04/
Q1604/97).
To maximize the likelihood of identifying medium penetrance
genetic variants influencing T2D-risk, a total of 591 individuals of
British ancestry, ascertained for early-adult onset (sample 1,
n=84), and/or family history of T2D (at least 1 sibling affected,
sample 2, n=507) were included (Table 1).
Sample 1 (the ‘‘Young Diabetes in Oxford Cohort’’) includes
subjects diagnosed with T2D between 18–45 years of age,
recruited from Oxfordshire GP practices. We excluded those with
type 1 diabetes (T1D) by requiring that all subjects had no
permanent requirement for insulin therapy within 12 months of
diagnosis and no evidence of islet autoimmunity (glutamic acid
decarboxylase (GAD) antibody levels ,14 WHO units/ml) [13].
The subjects classified as having T2D did not meet current clinical
criteria for MODY diagnostic testing [14] and all had demon-
strable fasting C-peptide levels (mean 0.8360.44 nmols/L [non-
diabetic reference range: 0.11–0.61 nmols/L]).
Sample 2 consists of probands from the Warren 2 sibpair
collection (W2SP): these have been described previously [15]. All
individuals in this group were diagnosed between 35 and 75 years
(mean age of diagnosis 55.4 years) and had at least one affected
sibling diagnosed with diabetes. Those with positive GAD
antibodies were excluded.
To establish the background allele frequency of variants
identified in this study in a UK control population, we utilised a
subset of the British Birth Cohort of 1958 (n=350 for the intronic
variants identified, n=1050 for the exonic variant identified)
[16,17].
Targeted capillary resequencing of exons 8–10 of HNF1A
(including intron-exon boundaries) was performed on the ABI3700
platform (Applied Biosystems, Warrington, UK) using standard
protocols (primer sequences are available on request). Sequences
were compared to the reference sequence (NM_000545.3) using
the unidirectional analysis mode of Mutation surveyor V3.2
(Biogene, Cambridge, UK). This software package has been
shown to have a sensitivity of .99% in the unidirectional analysis
mode[18]. We further checked the accuracy of calls by visual
inspection of all electropherograms. Power calculations using the
software package Quanto [19] demonstrated that we had 90%
power to detect a variant with a MAF of 1% and an OR of 2.5 for
a=0.05.
The background allele frequency of variants identified in this
study was established in a UK control population using custom
TaqMan assays (primer sequences included in supplementary
table S1) on the ABI 7900HT platform (n=350 for the 3 intronic
SNPS and n=1050 for the exonic variant identified). Genotype
quality was assessed by evaluating the genotyping success rate
(greater than 98% for all variants) and assessing whether there was
any departure from Hardy-Weinberg Equilibrium (none was
detected).
Results
We identified a total of 4 variants (three intronic and one
exonic) in resequencing the terminal 3 exons of HNF1A in 591
individuals (Table 2). However no novel coding variants (low
frequency or otherwise) was identified. We subsequently geno-
typed a subset of the British Birth Cohort of 1958 (n=350 for the
intronic variants identified and n=1050 for the exonic variant
identified) as noted above, to establish the MAF of the variants
identified in a UK population (Table 2). The only coding variant
identified (T515T, rs61953349) is a previously reported synony-
mous variant with a MAF of 14.6% in our cases and of 18.3% in
control individuals (p=0.056, using an exact implementation of
the Cochran Armitage trend test). For the 3 intronic variants, no
statistically significant differences in genotype frequencies were
noted between the cases and controls (calculated using an exact
implementation of the Cochran Armitage trend test (Table 2).
Discussion
In a recent study of MODY families showing classical
Mendelian segregation, individuals with mutations in exons 8–10
of HNF1A were noted to have been diagnosed as late as 38 years,
and the median age of diagnosis was ,27 years [3]. It was this
observation that led us to test the hypothesis that coding variants
within the same exons might be playing a role in the pathogenesis
of multifactorial T2D. Given that genome-wide association studies
Table 1. Characteristics of subjects with T2D.
Sample 1 Sample 2
N 84 507
Male (%) 61.9 53.6
Mean age at diagnosis (years)6SD 34.3611.4 55.468.5
*Treatment (ins/OHA/diet) (%) 26/66/8 14/69/17
First-degree relative with Diabetes (%) 48 100
Mean BMI (kg/m
2)6SD 32.364.8 28.865.2
*Treatment at the time of ascertainment. ins, insulin; OHA, oral hypoglycaemic
agent.
doi:10.1371/journal.pone.0006615.t001
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ular focus was on variants of relatively low frequency (in the 0.5–
5% range). If variants in this part of the allele frequency spectrum
have effect sizes greater than those so far observed for common
variants, they may be responsible for a substantial proportion of
the genetic variance of T2D.
In our study population, 60 (10%) individuals were diagnosed at
38.5 years or younger and the median age of diagnosis was 55
(compared to an average age of diagnosis in the UK of 59.6 years
[based on 15653 T2D patients from Tayside Scotland. R.
McAlpine & AD Morris, personal communication]). Almost all
cases had close relatives with T2D, a feature which is likely to
reflect enrichment for medium penetrance variants.
Despite these measures, we failed to detect any novel coding
variants in the terminal exons of HNF1A and can be confident that
there are no such variants with case allele frequencies exceeding
1.0%. Of course, we cannot exclude the possibility that additional
low-frequency susceptibility variants will be found in other regions
of this gene, nor in other genes known to be causal for monogenic
forms of diabetes. Recent advances in high throughput ‘‘next-
generation’’ resequencing technologies [24] now make it feasible
to deep-resequence multiple genes in large numbers of subjects in
a cost effective manner, and should enable these broader
hypotheses to be tested.
Supporting Information
Table S1 Assay by design sequences for genotyping of variants
detected in exons 8–10 of HNF1A
Found at: doi:10.1371/journal.pone.0006615.s001 (0.03 MB
DOC)
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